Allarity第三季末现金2410万美元：净亏损620万美元、研发开支420万美元，11月13日发布并给出第四季指引
二期临床阶段制药公司Allarity Therapeutics于2026年11月13日公布截至2026年9月30日的第三季业绩，并提供临床与业务进展。以下数字均出自公司业绩稿正文，稿件不作投资建议。
截至2026年9月30日，公司现金与受限现金为2410万美元，其中受限现金为1000万美元。
第三季研发开支为420万美元，上年同期为120万美元；一般与行政开支为130万美元，与上年同期持平。归属普通股股东的净亏损为620万美元，上年同期为280万美元，公司称同比增加主要来自一笔320万美元的一次性生产开支。
指引方面，公司预计第四季每股收益在0.01至0.04美元之间，并预计2026年全年每股亏损在0.73至0.76美元之间。公司注明这些数字为初步且未经审计，实际结果可能不同。
业务方面，公司在季后10月宣布其新设的CLIA认证实验室服务策略下的首份创收合同。公司开发中的stenoparib为一种双PARP与WNT通路抑制剂。
Allarity Ends the Third Quarter With 24.1 Million Dollars in Cash: A Net Loss of 6.2 Million Dollars and Research Spending of 4.2 Million Dollars, Released November 13 With Fourth-Quarter Guidance
Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, reported financial results for the third quarter ended September 30, 2026 on November 13, 2026, and provided an update on its clinical and business activities. All figures below are from the body of the company's release, and this report offers no investment advice.
As of September 30, 2026, Allarity had 24.1 million dollars in cash and restricted cash, including 10.0 million dollars in restricted cash.
Research and development expenses were 4.2 million dollars, compared with 1.2 million dollars in the third quarter of 2025. General and administrative expenses were 1.3 million dollars, unchanged from 1.3 million dollars a year earlier. The net loss attributable to common stockholders was 6.2 million dollars, compared with 2.8 million dollars a year earlier, and a 3.2 million dollar one-time manufacturing expense accounted for most of the year-over-year increase.
The company provided guidance for earnings of 0.01 to 0.04 dollars per share in the fourth quarter, and anticipates a full year 2026 loss between 0.73 and 0.76 dollars per share. The company noted these figures are preliminary and unaudited, and actual results may differ.
Subsequent to quarter-end, in October, Allarity announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy.
来源：Allarity Therapeutics
发布：GSM·美国（发布链接）
图片来源：图：美国国家卫生研究院细胞肿瘤学实验室（Allarity相关资料图）。National Institutes of Health，Public domain，Wikimedia Commons。 / Photo: 美国国家卫生研究院细胞肿瘤学实验室. National Institutes of Health, Public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
